| |
| |
|
| Insider
Information: |
Bvf Investments Llc |
| Relationship: |
See Explanation of Res... |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
17,080,641 |
|
|
Indirect Shares
|
18,830,194 |
|
|
| Direct
Value |
$849,401,993 |
|
|
|
Indirect Value
|
$549,856,755 |
|
|
| Total
Shares |
35,910,835 |
|
|
| Total
Value |
$1,399,258,748 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Arena Pharmaceuticals Inc |
ARNA |
Direct Beneficial Owner |
2004-06-16 |
0 |
2004-06-16 |
1,505,351 |
Premium* |
|
|
Aeolus Pharmaceuticals Inc |
AOLS |
Indirect Beneficial Ow... |
2005-11-21 |
760,000 |
2006-06-06 |
1,778,720 |
Premium* |
|
|
Sgx Pharmaceuticals, Inc. |
SGXP |
10% Owner |
2007-02-14 |
1,655,300 |
|
0 |
Premium* |
|
|
Neurobiological Technologies Inc |
NTII |
10% Owner |
2007-10-30 |
4,891,393 |
|
0 |
Premium* |
|
|
Ligand Pharmaceuticals Inc |
LGND |
See Explanation of Res... |
2008-11-06 |
9,773,948 |
2013-09-23 |
2,459,757 |
Premium* |
|
|
Gyre Therapeutics |
GYRE |
See Explanation of Res... |
2012-11-14 |
0 |
2012-11-16 |
2,063,389 |
Premium* |
|
|
Chemocentryx, Inc. |
CCXI |
See Explanation of Res... |
2013-09-11 |
0 |
2015-11-05 |
3,414,295 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
See Explanation of Res... |
2013-11-19 |
0 |
2013-11-19 |
7,608,682 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
35 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CCXI |
Chemocentryx, Inc. |
See Explanation of Responses |
– – – |
2015-11-02 |
4 |
S |
$6.97 |
$348,515 |
I/I |
(50,000) |
2,744,577 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
See Explanation of Responses |
– – – |
2015-11-03 |
4 |
S |
$6.98 |
$509,343 |
I/I |
(73,000) |
2,671,577 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
See Explanation of Responses |
– – – |
2015-11-04 |
4 |
S |
$7.00 |
$2,009,057 |
I/I |
(287,000) |
2,384,577 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
See Explanation of Responses |
– – – |
2015-06-09 |
4 |
S |
$9.00 |
$8,322,392 |
I/I |
(924,700) |
2,825,577 |
0 |
- |
|
| CCXI |
Chemocentryx, Inc. |
See Explanation of Responses |
– – – |
2015-06-10 |
4 |
S |
$9.01 |
$279,229 |
I/I |
(31,000) |
2,794,577 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
See Explanation of Responses |
– – – |
2012-10-31 |
4/A |
B |
$14.99 |
$61,096 |
I/I |
4,076 |
741,627 |
0.01 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
See Explanation of Responses |
– – – |
2012-10-26 |
4/A |
B |
$15.26 |
$190,926 |
I/I |
12,515 |
737,551 |
0.01 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
See Explanation of Responses |
– – – |
2012-12-06 |
4 |
B |
$17.94 |
$898,959 |
I/I |
50,100 |
2,118,426 |
0.01 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
See Explanation of Responses |
– – – |
2012-12-14 |
4 |
B |
$18.63 |
$100,365 |
I/I |
5,386 |
2,123,812 |
0.01 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
See Explanation of Responses |
– – – |
2013-09-23 |
4 |
S |
$44.50 |
$15,976,524 |
I/I |
(359,023) |
296,345 |
0 |
- |
|
35 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
